EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tackling the unyielding: testing two novel approaches against NDM-producing Enterobacterales and Pseudomonas aeruginosa isolates collected in India

Yamuna Devi Bakthavatchalam iD, Bijayini Behera, Anand Shah, Purva Mathur iD, Raja Ray, Bashir Ahmed Fomda, Kamini Walia, Balaji Veeraraghavan iD

Microbiology Spectrum · 2025

DOI: 10.1128/spectrum.00497-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, 2025. Verfasst von Yamuna Devi Bakthavatchalam und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Microbiology, Christian Medical College, Vellore, Tamil Nadu, India. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Microbial Sensitivity Tests, Anti-Bacterial Agents, beta-Lactamases. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The in vitro activity of two novel antibiotics with different modes of action, (i) siderophore cefiderocol and (ii) β-lactam-enhancer mechanism-based cefepime/zidebactam, was tested against New Delhi Metallo-β-lactamase (NDM)-producing Enterobacterales and Pseudomonas aeruginosa collected in India. Minimum inhibitory concentrations of antibiotics against multicentric NDM-producing Escherichia coli ( n = 117), Klebsiella pneumoniae ( n = 103), and P. aeruginosa ( n = 72) were determined by the reference broth microdilution method. Among E. coli , 111 isolates were NDM-alone, and six were NDM + OXA-48-like producers. Among K. pneumoniae , 47 and 56 isolates were NDM-alone and NDM + OXA-48-like producers, respectively. All E. coli isolates harbored four amino acid inserts in their penicillin-binding protein 3. Using the highest susceptible breakpoint among CLSI, FDA, and EUCAST interpretive criteria, cefiderocol susceptibility was 39.3%, ≤80%, and 57%, for NDM ± OXA-48-like-producing E. coli , NDM ± OXA-48-like-producing K. pneumoniae, and NDM-producing P. aeruginosa , respectively. At a cefepime break point of ≤8 mg/L, 100% of Enterobacterales and ≥90% of P. aeruginosa isolates were cefepime/zidebactam-susceptible. NDM being a dominant carbapenemase among Enterobacterales and P. aeruginosa in India, the variable activity of cefiderocol against NDM producers is a concern. Post approval, cefepime/zidebactam could offer a promising treatment option against NDM producers. IMPORTANCE Metallo-β-lactamases are therapeutically challenging due to the limited treatment options. Against such isolates, currently approved newer β-lactam/β-lactamase inhibitor combinations are ineffective. In this study, we tested siderophore cephalosporin, cefiderocol, which utilizes an unconventional iron uptake pathway for efficient cellular penetration, and cefepime/zidebactam that utilizes novel β-lactam enhancer mechanisms for overcoming diverse carbapenemases. Cefiderocol showed limited activity against Escherichia coli isolates co-harboring New Delhi metallo-β-lactamase (NDM) with PBP3 insert, dual carbapenemase (NDM with OXA-48 like)-producing Klebsiella pneumoniae , and NDM-producing Pseudomonas aeruginosa isolates, while cefepime/zidebactam potently inhibited NDM-producing Enterobacterales and P. aeruginosa isolates. NDM being a dominant carbapenemase among Enterobacterales and P. aeruginosa in India, the variable activity of cefiderocol against NDM producers is a concern. Post approval, cefepime/zidebactam could offer a promising treatment option against NDM producers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pseudomonas aeruginosaMicrobial Sensitivity TestsAnti-Bacterial Agentsbeta-LactamasesAzabicyclo CompoundsCephalosporinsCefiderocolKlebsiella pneumoniaeIndiaHumansEscherichia coliCyclooctanesEnterobacteriaceaePseudomonas InfectionsCefepimeBacterial ProteinsSiderophoresEnterobacteriaceae InfectionsDrug CombinationsPiperidines

Stichwörter der Autor:innen

IndiaNDMcefepime/zidebactamcefiderocol

Substanzen

Anti-Bacterial Agentsbeta-LactamasesAzabicyclo CompoundsCephalosporinsCefiderocolbeta-lactamase NDM-1cefepime-zidebactamCyclooctaneszidebactamCefepime

Autor:innen und Institutionen

  • Department of Clinical Microbiology, Christian Medical College, Vellore, Tamil Nadu, India.
  • Department of Microbiology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India.
  • Department of Microbiology, Zydus Hospitals, Ahmedabad, Gujarat, India.
  • Department of Clinical Microbiology, All India Institute of Medical Sciences, New Delhi, India.
  • Department of Microbiology, Institute of Post Graduate Medical Education and Research, Kolkata, India.
  • Department of Microbiology, Sher-i-Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India.

ORCID-Profile: Yamuna Devi Bakthavatchalam, Purva Mathur, Balaji Veeraraghavan

Zitieren

APA

Bakthavatchalam, Y. D., Behera, B., Shah, A., Mathur, P., Ray, R., Fomda, B. A., Walia, K., & Veeraraghavan, B. (2025). Tackling the unyielding: testing two novel approaches against NDM-producing Enterobacterales and Pseudomonas aeruginosa isolates collected in India. Microbiology Spectrum. https://doi.org/10.1128/spectrum.00497-24

Vancouver

Bakthavatchalam YD, Behera B, Shah A, Mathur P, Ray R, Fomda BA, et al. Tackling the unyielding: testing two novel approaches against NDM-producing Enterobacterales and Pseudomonas aeruginosa isolates collected in India. Microbiology Spectrum. 2025. doi:10.1128/spectrum.00497-24

BibTeX
@article{Bakthavatchalam2025,
  author = {Bakthavatchalam, Yamuna Devi and Behera, Bijayini and Shah, Anand and Mathur, Purva and Ray, Raja and Fomda, Bashir Ahmed and Walia, Kamini and Veeraraghavan, Balaji},
  title = {Tackling the unyielding: testing two novel approaches against NDM-producing Enterobacterales and Pseudomonas aeruginosa isolates collected in India},
  journal = {Microbiology Spectrum},
  year = {2025},
  doi = {10.1128/spectrum.00497-24}
}
Kostenlos starten →